IGM Biosciences ended last year laying off staff and streamlining its cancer pipeline. Now, the company has become the latest to join a hot trend in cell therapy biotech—pivoting from oncology to ...
IGM Biosciences announced they are halting the development of two investigational drugs for autoimmune and inflammatory diseases, imvotamab (an IgM-based CD20 X CD3 bispecific antibody T cell engager) ...
MOUNTAIN VIEW, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today ...
Extract: A girl who had had severe recurrent infections from the seventh year of life and who died from the sequelae of extensive bronchiectasis at 18 years of age was studied. The serum of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback